Guard Therapeutics: Positive Results
Research Note
2020-07-08
13:25
Redeye reiterate our valuation on Guard Therapeutics (ticker: GUARD) following positive news. Today Guard Therapeutics presented follow-up data on its phase 1A, single ascending dose (SAD) study. The results are positive and somewhat unexpected.
NF
JS
Nima Faroghi
Jakob Svensson
Disclosures and disclaimers